Standout Papers
Citation Impact
Citing Papers
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
2011 Standout
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study
2002
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
Immunotherapy of cancer in 2012
2012
Gastric cancer
2016 Standout
Sensitivity of Non-Small-Cell Lung Cancer Cell Lines Established from Patients Treated with Prolonged Infusions of Paclitaxel
2003
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
2000
Retinoic acid receptors: From molecular mechanisms to cancer therapy
2014
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Multidisciplinary weight management in locoregional breast cancer: results of a phase II study
1998
Biologic Characteristics of Interval and Screen-Detected Breast Cancers
2000
Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction
2001 Standout
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.
1995
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
The group psychotherapy and home‐based physical exercise (group‐hope) trial in cancer survivors: Physical fitness and quality of life outcomes
2003
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
2000
Adjuvant dietary fat intake reduction in postmenopausal breast cancer patient management
1991
The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients
1993
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial
1999
Insulin-like growth factors and neoplasia
2004
Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer
1999 Standout
Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: Failure patterns by cell type in rtog 88-08/ECOG 4588
1997
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
1995
Delayed emesis: incidence, pattern, prognostic factors and optimal treatment
2002
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
Metabolism and action of amino acid analog anti-cancer agents
1990
The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.
1993
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
2000
A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum
1997
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
1997 Standout
Microsatellite Instability and 8p Allelic Imbalance in Stage B2 and C Colorectal Cancers
1999
Classification and functions of enteroendocrine cells of the lower gastrointestinal tract
2011
Chemotherapy for advanced gastric cancer
2010
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
1997
Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status
2004
Factors influencing survival in high-grade gliomas
2003
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
2004 Standout
Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial
1997
Allelic Loss of Chromosome 18q and Prognosis in Colorectal Cancer
1994
Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer
1994
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
2009
A molecular signature of metastasis in primary solid tumors
2002 Standout
Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival
2004
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
1997
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
1996
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory Neural Pathways
2017 StandoutNobel
Epidemiology of Lung Cancer
2013
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine
2001
Nutrition and Physical Activity During and After Cancer Treatment: An American Cancer Society Guide for Informed Choices
2006
Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer
2004
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
2017
Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study.
1996
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
1997 Standout
Targeting gene expression to hypoxic tumor cells
1997 StandoutNobel
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
2005 Standout
Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer
2000
Determination of microsatellite instability,p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: Relationship with response to 5-fluorouracil and survival
2001
Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status
2000
A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
2001
Preoperative Radiotherapy for Resectable Rectal Cancer
2000
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
1992 Standout
Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
1990 Standout
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study
2005
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.
1997
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
2000 Standout
Mismatch Repair Deficiency in Phenotypically Normal Human Cells
1995 StandoutScienceNobel
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
2004
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
2008
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.
1993
Developing a cancer‐specific geriatric assessment
2005
Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer
2002
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer
2002
Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer
2005
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Frontline Treatment of Advanced Gastric Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor (G-CSF)
2000
Brain Tumors
2001 Standout
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer
1997
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study
2004
A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
1999
Riding the Crest of the Teachable Moment: Promoting Long-Term Health After the Diagnosis of Cancer
2005 Standout
Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy
2005
Feasibility of using volunteer research staff to deliver and evaluate a low-fat dietary intervention: the American Cancer Society Breast Cancer Dietary Intervention Project.
1997
Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized Trial
2002
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
2004
Nutrition and Survival After the Diagnosis of Breast Cancer: A Review of the Evidence
2002
Structure of the STRA6 receptor for retinol uptake
2016 StandoutScienceNobel
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
2003
Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study
2002
Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205)
2002
Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized Trial
2003
Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications
2005
Clinical Trial to Assess the Relative Efficacy of Fluorouracil and Leucovorin, Fluorouracil and Levamisole, and Fluorouracil, Leucovorin, and Levamisole in Patients With Dukes' B and C Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project C-04
1999
Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431
2002
Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life
1999
Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer
2009
Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results
2001
Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer
2007
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial
2005
Preventing sarcopenic obesity among breast cancer patients who receive adjuvant chemotherapy: results of a feasibility study.
2002
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
2002
Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations
2006
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
1999
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
2003 Standout
Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent Panel
2001
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
2013
Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer
2000
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
2006
Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1.
1998
Weight Loss in Breast Cancer Patient Management
2002
Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer
1995
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
2008
Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer
2003
Cancer Genome Landscapes
2013 StandoutScience
Radiosensitization With Carboplatin for Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: A Phase III Trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group
1999
Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers
2005
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Contribution of Dexamethasone to Control of Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Evidence
2000
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Enzymatic aminoacylation of tRNA with unnatural amino acids
2006 StandoutNobel
Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer
1997 Standout
Biallelic inactivation of hMLH 1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers
1998 StandoutNobel
Interferons, immunity and cancer immunoediting
2006
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
2012
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
2004
Works of James E. Krook being referenced
Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma
1997
Measurable or assessable disease in lung cancer trials: does it matter?
1994
Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer.
1994
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594
2001
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
1997
Combination hormonal therapy with tamoxifen plus fluoxymesteroneversus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis
1991
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy
1997
Prevalence and prognostic significance of neuroendocrine differentiation in colorectal carcinomas
1998
Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group.
1994
Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma.
1993
A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma
1999
Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer
1989
Thoracic Radiation Therapy Alone Compared with Combined Chemoradiotherapy for Locally Unresectable Non-Small Cell Lung Cancer
1991
Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer.
1995
Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer.
1991
Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma
1991
Evaluation of shark cartilage in patients with advanced cancer
2005
Results of combined‐modality therapy for limited‐stage small cell lung carcinoma in the elderly
2005
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
1998
Improving Adjuvant Therapy for Rectal Cancer by Combining Protracted-Infusion Fluorouracil with Radiation Therapy after Curative Surgery
1994
Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors
1999
Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group.
1994
DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials.
1993
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.
1989
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
1989
p53 Gene Expression in Node-Positive Breast Cancer: Relationship to DNA Ploidy and Prognosis
1994
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
2002 Standout
Bolus Versus Infusion Regimens of Etoposide and Cisplatin in Treatment of Non-Small Cell Lung Cancer: A Study of the North Central Cancer Treatment Group
1990
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
1990
Cyclophosphamide-Cisplatin Versus Cyclophosphamide-Carboplatin in Stage III-IV Ovarian Carcinoma: A Comparison of Equally Myelosuppressive Regimens
1989
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.
1994
Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer.
1997
Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer.
1988
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
1985
NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer
2008
Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer.
1986
Adjuvant treatment of rectal cancer: Randomized prospective study of irradiation ± chemotherapy — A NCCTG, Mayo clinic study
1986
A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.
1985
Brief Physician-Initiated Quit-Smoking Strategies for Clinical Oncology Settings: A Trial Coordinated by the Eastern Cooperative Oncology Group
2003
Comparison of combination chemotherapy programs in advanced adenocarcinoma-large cell carcinoma of the lung: a North Central Cancer Treatment Group study.
1984